Mytos

Mytos is a London-based biotechnology and automation company that develops iDEM, a system that automates the unit operations of cell culture, and operates an automated contract development and manufacturing organisation (CDMO) for regenerative medicines. The company positions its technology as a way to produce stem cell-derived therapies at scale and lower cost per dose, covering both autologous and allogeneic production, cell banking and differentiation, and supporting multiple T-flask sizes in a closed system.

The iDEM platform uses the same 2D T-flask format as manual culture, which the company says allows manual protocols to be ported to closed automation without altering the underlying biology. Mytos states iDEM reduces labour per batch by up to 10x versus manual culture and reduces cleanroom footprint per batch by a further 10x, and that a fleet architecture avoids the single point of failure associated with large robotic-arm systems. Validated and demonstrated applications include pluripotent stem cell expansion and cell banking, neural progenitor differentiation (relevant to Parkinson's disease), cardiomyocyte differentiation for chronic heart failure research, and retinal pigment epithelium differentiation for macular degeneration.

Mytos CDMO's first site is housed within the Cell and Gene Therapy Catapult's 80,000 sq ft facility, with the company stating plans for a series of global sites. Alongside manufacturing, Mytos says it covers process and analytical development and regulatory support through its own team and partners.

Founding story

The founders observed that regenerative therapies were demonstrating the potential to treat Parkinson's disease, blindness and spinal cord injury, but that manual production would keep them unaffordable and inaccessible for most patients, and set out to address this with automated production. The company began by automating production of stem cell-derived cells such as heart and brain tissue for R&D use at large US pharmaceutical companies, including three of the top 20.

Business model

Mytos operates as an automated CDMO, manufacturing cells for clinical-stage regenerative medicine developers using its own iDEM devices rather than selling the hardware to customers. The company states there are no suite fees and no requirement for customers to purchase iDEM devices, with revenue instead tied to manufacturing batches; it claims batch costs up to 50% lower than manual CDMOs. Services span process and analytical development through to regulatory support, delivered with partners.

Manufacturing services billed per batch, with the company stating it charges no cleanroom suite fees and does not require customers to buy iDEM equipment.

Traction

Announced manufacturing collaborations include Aspen Neuroscience (January 2025), for automating production of autologous dopaminergic neuronal precursor cells for the ANPD001 Parkinson's program to be integrated into Aspen's 22,000 sq ft facility; StemSight, Rinri Therapeutics and Novadip (September 2025), covering corneal blindness, hearing loss and bone regeneration; and Pluristyx (reported December 2025) to automate manufacture of clinical-grade iPSC lines. Mytos CDMO Site 1 operates within CGT Catapult's 80,000 sq ft site. The company reports having raised over $24M in total.

Latest developments

In September 2025 Mytos announced strategic partnerships with StemSight, Rinri Therapeutics and Novadip covering cell therapies for corneal blindness, hearing loss and bone regeneration. A strategic collaboration with Pluristyx to automate manufacture of clinical-grade iPSC lines was reported in December 2025.